Found "Early HTA": 383 results
Sort by
Last updated

Off-label medicines: Rational or Irrational?

The use of off-label medicines is an unexplored area for healthcare priority setting, though it is common practice in countries and can have a significant positive or negative effect on health outcomes and the efficiency of health care systems. It is therefore important to have a rational an

Using Health Technology Assessment to address inefficient and unequal use of Nilotinib across Indonesia

It is vital to have evidence-informed clinical practice guidelines or clinical indications to guide the usage of high-cost drugs in the benefits package under the Indonesian universal health coverage (JKN), managed by BPJS Kesehatan. A transparent and legit mechanism is required to support and mo

Should high-cost bevacizumab be used for metastatic-colorectal cancer (mCRC) treatment in JKN in Indonesia?

Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage. Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca

Evaluating the Value of a Real-World HTA Agency

As countries develop their health systems on the path to Universal Health Coverage (UHC) (#LeaveNoOneBehind), many countries are experimenting with the development of a health technology assessment (HTA) agency in order to set priorities for health benefit packages, make go/no go decisions about

Early HTA: A Guide for Developing Pulmonary Tuberculosis Cost-Effective Tests Fitting the Healthcare Needs

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and represents a significant global health concern. Infectious agents can be easily spread through respiratory droplets, and TB patients face a significant risk of mortality. The traditional sputum-based TB

Experience in Using HTA for Expanding UHC Benefit Package to Cover Rare Diseases and High-Cost Drugs among Seven Middle and High-Income Countries: A targeted literature review

This policy brief provides a summary of a recent review of the definition of rare diseases, high cost and how HTA has been used in the case of rare diseases in seven countries. The countries were purposively selected based on them having established HTA policies and availability of resources in the

Strategies for Sustainable Access: Unpacking Managed Entry Agreements (MEAs) and Innovative Medicine Access

MEAs aim at early access to high-cost innovative medicines at pre-determined terms that can ensure the financial sustainability of healthcare systems. However, their successful adoption hinges on a consideration of various factors to address the unique challenges faced by different nations. The a

Cost-Effectiveness of Cascade Testing for Familial Hypercholesterolemia in Thailand: A Comparative Analysis of Genome Sequencing Methods Across Development Stages

Familial Hypercholesterolemia (FH) is a genetic disorder characterized by elevated cholesterol levels, significantly increasing the risk of heart disease. Early detection through genetic screening can play a crucial role in preventing serious health outcomes. This study marks the first global eco

Thalidomide victims: drugmaker’s apology not enough

(Reuters) – Victims of thalidomide said on Saturday an apology from the German inventor of the drug that caused birth defects in thousands of babies around the world was too little too late.Thalidomide, developed by the German firm Gruenenthal, was marketed internationally to pregnant women in the l

Photo Album HTAsialink 2018

HTAsiaLink 20188-11 May 2018, Chiang Mai, ThailandMore than 200 participants from over 30  HTA organizations and other academic and policy making agencies across the global joined this conference!The themes of this years’ conference is Testing Treatments: Strengthening HTA for better healthcare.For
10 / Page